BioLife Solutions, Inc. BLFS

BioLife Solutions (BLFS) is a leader in advanced preservation solutions for cellular matter, with strong technical momentum and a recent 3-year high. Shares are up nearly 60% over the past year. BLFS maintains a 100% “Buy” technical rating and a Trend Seeker “Buy” signal. Analyst sentiment is mixed, with most...

Diamond Hill Capital, a First Eagle Investment Management company, issued its Q2 2026 investor letter for its “Small Cap Strategy”. The letter can be downloaded here. The strategy returned 24.01% in the second quarter, outperforming the Russell 2000 Index’s 21.49% return. Performance was positively affected by stock selection in health care and industrials, while the Fund’s underweight position […]

In the past quarter, BioLife Solutions, Inc. reported second‑quarter 2026 sales of US$28.47 million, up from US$23.44 million a year earlier, with net income improving to US$45.10 million from a net loss of US$15.84 million. This shift from loss to earnings, including basic earnings per share from continuing operations moving to US$0.92 from a loss of US$0.32, signals a significant change in the company’s recent operating performance. With this sharp move from loss to profit, we’ll examine...

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, announces financial results for the three and six months ended June 30, 2026.

Repligen (NasdaqGS:RGEN) and BioLife Solutions recently held a merger and acquisition call. The discussion focused on potential combinations or partnerships in bioprocessing and cell and gene therapy tools. The call represents new corporate activity that is separate from routine earnings updates. Repligen enters this M&A discussion with BioLife Solutions while its shares trade at $131.06. The stock is up 9.5% over the past year, although it is down 20.3% year to date and has declined 23.6%...

Repligen Corporation (NASDAQ:RGEN) reported double-digit second-quarter revenue growth and increased its full-year 2026 financial guidance, citing strong order momentum and continued market outperformance while highlighting its pending acquisition of BioLife Solutions. Key Investor TakeawaysRepligen raised its full-year 2026 guidance following stronger first-half performance and continued order momentum.

Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index down 0.4% and th

Repligen (NASDAQ:RGEN) said it has signed a definitive agreement to acquire BioLife Solutions in a transaction valued at approximately $1.5 billion, adding a cell therapy-focused platform that management said will expand Repligen’s exposure to one of the faster-growing areas of bioprocessing. Presi

Fast-tracks Repligen’s leadership and customer solution offering in high-growth cell therapy market by adding BioLife’s differentiated, high-margin recurring revenue business BioLife stockholders to receive cash and Repligen common stock at a value of $31.00 per share, representing a total enterprise value of approximately $1.5 billion Compelling financially, the transaction is expected to be accretive to Repligen’s top-line growth, adjusted margins, and adjusted earnings per share by at least 5

Prosper Stars & Stripes, a long/short equity fund, recently released its first-quarter 2026 investor letter. A copy of the letter is available to download here. In Q1 2026, the portfolio underperformed with a net return of (-5.6%) compared to the Russell 2000 Index’s +0.9% return and the HFRX Equity Hedge Index’s -1.5% return. Long book performance […]